Details for Patent: 11,124,526
✉ Email this page to a colleague
Which drugs does patent 11,124,526 protect, and when does it expire?
Patent 11,124,526 protects EXBLIFEP and is included in one NDA.
This patent has seventeen patent family members in twelve countries.
Summary for Patent: 11,124,526
Title: | Crystalline beta-lactamase inhibitor |
Abstract: | A crystalline compound of formula (I): |
Inventor(s): | Lamonica Alessandro, Forzatti Marco, Biondi Stefano |
Assignee: | Allecra Therapeutics SAS |
Application Number: | US16177406 |
Patent Claim Types: see list of patent claims | More… ↓ |
Drugs Protected by US Patent 11,124,526
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allecra Theraps | EXBLIFEP | cefepime hydrochloride; enmetazobactam | POWDER;INTRAVENOUS | 216165-001 | Feb 22, 2024 | DISCN | Yes | No | 11,124,526 | ⤷ Subscribe | USE OF SPECIFIED POLYMORPHS OF EXBLIFEP (CEFEPIME AND ENMETAZOBACTAM) FOR TREATING COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY DESIGNATED SUSCEPTIBLE MICROORGANISMS | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,124,526
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2014345507 | ⤷ Subscribe | |||
Canada | 2929199 | ⤷ Subscribe | |||
Chile | 2016001097 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |